[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401708":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":25,"responsibleParty":48,"collaborators":50,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Oncology Institute of Southern Switzerland","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Part A",null,"Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions",{"label":13,"type":10,"description":14,"interventionNames":10},"Part B","FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for \"liquid biopsy\" will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent\n\n(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of \"liquid biopsy\" for future analysis.",[16],{"name":17,"affiliation":18,"role":19},"Ilaria Colombo, MD","Oncology Institute of Southern Switzerlan","PRINCIPAL_INVESTIGATOR",[21],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","+41 (0)91 811 8194","ilaria.colombo@eoc.ch",[26],{"facility":5,"status":27,"city":28,"state":10,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Bellinzona","6500","Switzerland","CH",{"type":33,"coordinates":34},"Point",[35,36],9.01703,46.19278,{"lat":36,"lon":35},[39,40,42,44,46],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":41,"role":19,"phone":10,"phoneExt":10,"email":10},"Anastasios Stathis, PD MD",{"name":43,"role":19,"phone":10,"phoneExt":10,"email":10},"Milo Frattini, PhD",{"name":45,"role":19,"phone":10,"phoneExt":10,"email":10},"Francesco Bertoni, Prof. MD",{"name":47,"role":19,"phone":10,"phoneExt":10,"email":10},"Davide Rossi, Prof. MD",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51,53],{"name":52,"class":6},"Ente Ospedaliero Cantonale, Bellinzona",{"name":54,"class":6},"Istituto Cantonale di Patologia","100401708","tumor-molecular-profiling-in-early-phase-clinical-trials-100401708",false,"NCT04510766","Tumor Molecular Profiling in Early Phase Clinical Trials","Molecular Characterization of Solid Tumors and Lymphomas to Optimize the Drug Development Process and Patients Enrollment in Early Phase Clinical Trials","Inclusion Criteria:\n\n1. Male or female patients age at least 18 years.\n2. Patients with histological diagnosis of advanced solid tumor or lymphoma who are potential candidates for early phase clinical trials.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n4. Live expectancy of at least 6 months.\n5. Availability of FFPE archival tumor tissue from previous surgery or diagnostic biopsy adequate for molecular analysis.\n6. Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure.\n7. Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n1. Presence of any clinical (e.g. concomitant disease, clinically significant symptoms, or non-clinical (psychological or social) conditions that would not make the patient eligible for enrolment in an early phase clinical trial.\n2. Any other active malignancy (other than the one for which the subject is being assessed for trial option) that is progressing or requiring active treatment with the exception of basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.","ALL","18 Years",{"count":65,"type":66},40,"ESTIMATED","OBSERVATIONAL","Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.",[70,71],"Advanced Solid Tumor","Lymphoma","2025-11-14",{"date":74,"type":75},"2025-11-18","ACTUAL",{"date":77,"type":75},"2020-10-01",{"date":79,"type":66},"2026-12-31",{"name":5,"class":6},1]